VNDA

Vanda Pharmaceuticals earns a Neutral rating, with a 44.2 composite score and low 2/5 conviction. Fundamentals provide the strongest pillar at 50.0, narrowly ahead of regulatory at 49.0, while market at 40.0 and editorial at 30.0 restrain the profile. The fundamentals score rests primarily on a near-perfect gross-margin subscore, supported by mid-tier market capitalization and modest revenue growth contributions. Those positives are sharply offset by minimal operating-margin credit and a weak cash-runway subscore, consistent with the stated stretched financial condition. Regulatory scoring benefits from a strong enforcement subscore, but limited filing cadence reduces the pillar’s contribution.

Licensed fundamentals data show year-over-year revenue growth of roughly 3.4% and a gross margin near 94.2%, demonstrating strong product-level economics. That strength fails to reach the operating line: the operating margin stands near negative 97.1%, net income is approximately negative $240 million, and EBITDA is approximately negative $152 million. A cash-burn ratio near 0.41 reinforces the stretched assessment despite the exceptional gross margin. Primary regulatory filings show no recorded events during either the past 90 days or the broader 180-day period, no enforcement hits, and no available latest-filing timestamp; that combination explains the high enforcement contribution and weak cadence score. Institutional pricing feeds provide no current quote, limiting market-pillar support, while CIN newsroom coverage records no newsroom or brief activity, leaving editorial contribution at its baseline level.

The forward catalyst sits squarely within fundamentals, the strongest pillar: conversion of the near-94% gross margin into materially better operating performance would lift the weakest fundamental subscore and improve confidence in the Neutral rating. Revenue growth currently offers only modest support, so incremental sales without expense discipline would leave the negative operating margin, negative EBITDA, and bottom-line loss as dominant constraints. A stronger filing cadence could improve regulatory visibility, but it carries less rating leverage than operating execution because fundamentals already lead the pillar set. The single most important signal to watch is sustained operating-margin improvement that demonstrates whether exceptional gross profitability can translate into lower losses and reduced cash consumption.